← Eichor
Study identifier: NCT04967976 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Breast Mesh Used in Two-staged Breast Reconstruction

Condition: Breast Cancer · Radiation · Breast Reconstruction  ·  Sponsor: Tianjin Medical University Cancer Institute and Hospital

PhaseNA
Planned participants300
Who can joinFemale, 18 Years to 70 Years
Healthy volunteersNo

About this study

This is the first prospective randomized and controlled study on the efficacy and safety of TiLOOP® Bra mesh in patients with expander-implant breast reconstruction. The investigators hypothesize that incoporating TiLOOP Bra mesh with tissue expanders will reduce the rates of capsular contraction, improve the efficiency of expansion and provide better aesthetic result.

This description comes directly from the study's public registry record.

Talk to the study team

Jian Yin  ·  +86-22-23340123  ·  yinjian@tjmuch.com

Bowen Ding  ·  +86-22-23340123  ·  ding_x87@126.com

Always discuss trial participation with your own doctor first.

Locations (6)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting
Gansu Provincial Cancer HospitalLanzhou, Gansu, ChinaRecruiting
Jilin Cancer HospitalCh’ang-ch’un, Jilin, ChinaRecruiting
Tianjin Medical University Cancer Institute and HospitalTianjin, Tianjin Municipality, ChinaRecruiting
Zhejiang Provincial People's HospitalHangzhou, Zhejiang, ChinaRecruiting
Technical University of MunichMunich, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04967976